The ReActiv8 trial involves patients with a mean age of 43.9 years and a history of low back pain. The patients previously received physical therapy and 70 percent took opioids for pain.
Here are three observations:
1. The new results from the trial indicate lasting improvement in pain, disability and quality of life.
2. At 90 days, 63 percent of subjects showed improvement in low back pain on the Numerical Rating Scale.
3. At 90 days, 57 percent of subjects demonstrated improvement on the Oswestry Disability Index, and 67 percent of subjects showed improvement on the EQ-5D scale.
More articles on devices:
SI-BONE, Aurora Spine, Xtant Medical & more — 25 key notes
NuVasive President & COO Patrick Miles sells 5k shares: 4 points
New study and licensing agreement for InVivo Therapeutics — 3 key points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
